FDA rejects UniQure's AMT-130 data, sending shares tumbling as the company scrambles to find a path forward.
Troubling rise in American acceptance of political violence, especially among younger adults, with over one-third under 45 believing it can be justified.
FDA rejects UniQure's AMT-130 data, sending shares tumbling as the company scrambles to find a path forward.
Troubling rise in American acceptance of political violence, especially among younger adults, with over one-third under 45 believing it can be justified.